Aurora Investment Counsel Has $1.39 Million Stake in Neurocrine Biosciences, Inc. $NBIX

Aurora Investment Counsel boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 4.8% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 11,027 shares of the company’s stock after buying an additional 507 shares during the period. Aurora Investment Counsel’s holdings in Neurocrine Biosciences were worth $1,386,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Dodge & Cox boosted its stake in Neurocrine Biosciences by 83.5% in the 1st quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock valued at $612,129,000 after buying an additional 2,518,199 shares in the last quarter. Wellington Management Group LLP boosted its stake in Neurocrine Biosciences by 44.0% in the 1st quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock valued at $232,037,000 after buying an additional 640,556 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Neurocrine Biosciences by 3.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company’s stock valued at $170,281,000 after buying an additional 49,088 shares in the last quarter. Braidwell LP boosted its stake in Neurocrine Biosciences by 32.2% in the 1st quarter. Braidwell LP now owns 1,191,925 shares of the company’s stock valued at $131,827,000 after buying an additional 290,135 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Neurocrine Biosciences by 8.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,159,367 shares of the company’s stock valued at $128,226,000 after buying an additional 89,271 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 106,322 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $126.41, for a total value of $13,440,164.02. Following the transaction, the director owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. This represents a 17.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Stock Up 0.9%

Shares of NBIX opened at $141.33 on Tuesday. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $154.61. The firm has a market capitalization of $14.02 billion, a PE ratio of 41.81, a price-to-earnings-growth ratio of 1.01 and a beta of 0.21. The stock’s fifty day simple moving average is $139.00 and its 200-day simple moving average is $126.56.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The firm had revenue of $687.50 million for the quarter, compared to analyst estimates of $653.09 million. During the same quarter in the prior year, the firm posted $1.63 earnings per share. The company’s quarterly revenue was up 16.5% on a year-over-year basis. Analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on NBIX shares. Guggenheim boosted their price target on Neurocrine Biosciences from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Needham & Company LLC boosted their price objective on Neurocrine Biosciences from $161.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, September 22nd. Wall Street Zen raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences from $140.00 to $145.00 and gave the stock a “neutral” rating in a research note on Thursday, July 31st. Finally, The Goldman Sachs Group assumed coverage on Neurocrine Biosciences in a research note on Thursday, July 10th. They issued a “buy” rating and a $182.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $163.72.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.